de Souza, Noel J. Gupte, Shrikant V. Deshpande, Prasad K. Desai, Vijaya N. Bhawsar, Satish B. Yeole, Ravindra D. Shukla, Milind C. Strahilevitz, Jacob Hooper, David C. Bozdogan, Bülent Appelbaum, Peter C. R. Jacobs, Michael Shetty, Nitin Patel, Mahesh V. Jha, Rasendrakumar Khorakiwala, Habil F. A Chiral Benzoquinolizine-2-carboxylic Acid Arginine Salt Active against Vancomycin-Resistant <i>Staphylococcus </i><i>a</i><i>ureus</i> There is an urgent medical need for novel antibacterial agents to treat hospital infections, specially those caused by multidrug-resistant Gram-positive pathogens. The need may also be fulfilled by either exploring antibacterial agents having new mechanism of action or expanding known classes of antibacterial drugs. The paper describes a new chemical entity, compound <b>21</b>, derived from hitherto little known “floxacin”. The choice of the entity was made from a series of synthesized prodrugs and salts of the active chiral benzoquinolizine carboxylic acid, <i>S</i>-(−)-nadifloxacin. The chemistry, physicochemical characteristics, and essential bioprofile of <b>21</b> qualifies it for serious consideration as a novel drug entity against hospital infections of multi-drug-resistant <i>Staphylococcus aureus</i>, and its progress up to clinical phase I trials in humans is described. Staphylococcu;hospital infections;agent;novel drug entity;chiral benzoquinolizine carboxylic acid 2005-08-11
    https://acs.figshare.com/articles/journal_contribution/A_Chiral_Benzoquinolizine_2_carboxylic_Acid_Arginine_Salt_Active_against_Vancomycin_Resistant_i_Staphylococcus_i_i_a_i_i_ureus_i_/3273289
10.1021/jm050035f.s001